intracranial thrombosis
Recently Published Documents


TOTAL DOCUMENTS

15
(FIVE YEARS 5)

H-INDEX

6
(FIVE YEARS 1)

Author(s):  
Michelangelo Mancuso ◽  
Dario Luca Lauretti ◽  
Nadia Cecconi ◽  
Massimo Santini ◽  
Valentina Lami ◽  
...  

Author(s):  
Nayara M. Pereira ◽  
Luiz A. Vieira Netto ◽  
Luís Felipe A. Peres ◽  
Alice J. Zaccariotti ◽  
Lígia G. Ribeiro ◽  
...  

2021 ◽  
Vol 10 (8) ◽  
pp. e39810817428
Author(s):  
Leonardo Soares Ribeiro Alves da Rocha ◽  
Maria Eduarda Barres Vieira ◽  
Angélica Augusta Grigoli Dominato

O objetivo do estudo foi relacionar as pesquisas sobre trombose venosa cerebral com o uso de anticoncepcionais orais combinados. Trata-se de uma revisão integrativa da literatura realizada através das bases de dados: LILACS, Scielo, Periódicos Capes, Medline PubMed, Cochrane Library e Science Direct, utilizando os descritores: “contraceptive agents”, “intracranial embolism thrombosis”, "thrombosis" “intracranial thrombosis”. Para a seleção de artigos foi utilizado o operador booleano “AND” entre os descritores. A pergunta norteadora, elaborada através da metodologia de PICO (Paciente, Intervenção, Controle, Outcome), foi: "Os anticoncepcionais orais desencadeiam a trombose venosa cerebral?”. Nos resultados foram encontrados 47 artigos, sendo 35 excluídos por não apresentarem relação entre trombose venosa cerebral e anticoncepcionais orais. Dessa forma, foram selecionados 12 artigos para compor essa revisão. No estudo pode-se concluir que, o risco dos eventos trombóticos venosos, em usuárias de anticoncepcionais orais combinados, está aumentado. Isto posto, é importante enfatizar o uso racional desses medicamentos, assim como a compreensão para o diagnóstico precoce da trombose venosa cerebral.


2021 ◽  
Vol 14 (4) ◽  
pp. e239359
Author(s):  
Sairam Raghavan ◽  
Sriram Gonakoti ◽  
Luis Parra-Rodriguez

The authors present a case of a 42-year-old previously healthy man who presented in sepsis, with right lateral gaze palsy. He was found to have bilateral cavernous sinus thrombosis (CST) and bilateral internal jugular thrombosis in the setting of Staphylococcus aureus bacteraemia. The patient was successfully treated and recovered from his illness after a protracted stay in the medical intensive care unit. We go over the treatment course and follow-up of this patient and discuss the need to have a high degree of clinical suspicion for CST and suppurative thrombophlebitis of the internal jugular veins. We also discuss the possible role of the Panton-Valentine leukocidin in causing thrombotic complications of S. aureus bacteraemia.


2019 ◽  
Vol 33 (9) ◽  
pp. 1195-1201 ◽  
Author(s):  
Yu Hu ◽  
Ziying Li ◽  
Wei Shi ◽  
Yanxue Yin ◽  
Heng Mei ◽  
...  

Cerebral thrombosis disease is a worldwide problem, with high rates of morbidity, disability, and mortality. Magnetic resonance imaging diffusion-weighted imaging was used as an important early diagnostic method for cerebral thrombotic diseases; however, its diagnosis time is 2 h after onset. In this study, we designed EGFP–EGF1–NP–Fe3O4 for earlier diagnosis of cerebral thrombosis by taking advantage of EGFP–EGF1 fusion protein, in which EGF1 can bind with tissue factor and enhanced green fluorescent protein has previously been widely used as a fluorescent protein marker. EGFP–EGF1–NP–Fe3O4 or NP–Fe3O4 reaches the highest concentration in the infarction areas in 1 h. To evaluate the targeting ability of EGFP–EGF1–NP–Fe3O4, a fluorochrome dye, Dir, was loaded into the nanoparticle. As shown by the in vivo organ multispectral fluorescence imaging, Dir-loaded EGFP–EGF1–NP–Fe3O4 exhibited higher fluorescence than those of model rats treated with Dir-loaded NP–Fe3O4. Coronal frozen sections and transmission electron microscope further showed that EGFP–EGF1–NP–Fe3O4 was mainly accumulated in the tissue factor exposure region of brain. The data indicated that the EGFP–EGF1–NP–Fe3O4 targeted cerebral thrombosis and might be applied in the early diagnosis of intracranial thrombosis.


2011 ◽  
Vol 70 (10) ◽  
pp. 1726-1732 ◽  
Author(s):  
J G Hanly ◽  
M B Urowitz ◽  
L Su ◽  
S-C Bae ◽  
C Gordon ◽  
...  

ObjectiveNeuropsychiatric events occur unpredictably in systemic lupus erythematosus (SLE) and most biomarker associations remain to be prospectively validated. This study examined a disease inception cohort of 1047 SLE patients to determine which autoantibodies at enrolment predicted subsequent neuropsychiatric events.MethodsPatients with a recent SLE diagnosis were assessed prospectively for up to 10 years for neuropsychiatric events using the American College of Rheumatology case definitions. Decision rules of graded stringency determined whether neuropsychiatric events were attributable to SLE. Associations between the first neuropsychiatric event and baseline autoantibodies (lupus anticoagulant (LA), anticardiolipin, anti-β2 glycoprotein-I, anti-ribosomal P and anti-NR2 glutamate receptor) were tested by Cox proportional hazards regression.ResultsDisease duration at enrolment was 5.4±4.2 months, follow-up was 3.6±2.6 years. Patients were 89.1% female with mean (±SD) age 35.2±13.7 years. 495/1047 (47.3%) developed one or more neuropsychiatric event (total 917 events). Neuropsychiatric events attributed to SLE were 15.4% (model A) and 28.2% (model B). At enrolment 21.9% of patients had LA, 13.4% anticardiolipin, 15.1% anti-β2 glycoprotein-I, 9.2% anti-ribosomal P and 13.7% anti-NR2 antibodies. LA at baseline was associated with subsequent intracranial thrombosis (total n=22) attributed to SLE (model B) (HR 2.54, 95% CI 1.08 to 5.94). Anti-ribosomal P antibody was associated with subsequent psychosis (total n=14) attributed to SLE (model B) (HR 3.92, 95% CI 1.23 to 12.5, p=0.02). Other autoantibodies did not predict neuropsychiatric events.ConclusionIn a prospective study of 1047 recently diagnosed SLE patients, LA and anti-ribosomal P antibodies are associated with an increased future risk of intracranial thrombosis and lupus psychosis, respectively.


CNS Spectrums ◽  
2005 ◽  
Vol 10 (7) ◽  
pp. 553-566 ◽  
Author(s):  
Jesse Weinberger

AbstractAtherosclerotic disease accounts for ~25% of ischemic strokes. Atherosclerotic stroke is caused mainly by embolic events from the carotid artery bifurcation or the aortic arch, although intracranial thrombosis can occur, more often in African Americans, Asians, and diabetes patients. Primary prevention of stroke is critical for patients with risk factors for atherosclerosis, including hypertension, diabetes, smoking and hypercholesterolemia. Stroke can be prevented in patients with established atherosclerotic disease by identification and management of patients with carotid artery stenosis by non-invasive testing. Particular attention must be paid to patients with transient symptoms of brain ischemia.


2005 ◽  
Vol 131 (5) ◽  
pp. 430 ◽  
Author(s):  
Eike Gunther Wüstenberg ◽  
Christian Offergeld ◽  
Thomas Zahnert ◽  
Karl-Bernd Hüttenbrink ◽  
Thomas Kittner

2002 ◽  
Vol 116 (3) ◽  
pp. 216-218 ◽  
Author(s):  
Andrew Hope ◽  
Nigel Bleach ◽  
Sabour Ghiacy

Lemierre’s syndrome comprises internal jugular vein thrombosis following oropharyngeal sepsis and is a rare and serious condition. It is most commonly caused by the anaerobe Fusobacterium necrophorum and typically presents as metastatic sepsis to the lungs and joints. Thrombosis is demonstrated by computed tomography (CT) of the neck, and it is routinely treated with intravenous antibiotics and anti-coagulation.We describe a case of Lemierre’s syndrome following acute supraglottitis. The clinical features were of retrograde intracranial thrombosis, rather than the more usual metastatic sepsis.


The Lancet ◽  
1976 ◽  
Vol 308 (7975) ◽  
pp. 49 ◽  
Author(s):  
E. Rydin ◽  
P.O. Lundberg

Sign in / Sign up

Export Citation Format

Share Document